idelalisib   Click here for help

GtoPdb Ligand ID: 6741

Synonyms: CAL-101/CAL101 | GS-1101 | Zydelig®
Approved drug PDB Ligand Immunopharmacology Ligand
idelalisib is an approved drug (FDA & EMA (2014))
Compound class: Synthetic organic
Comment: Idelalisib is highly selective and potent oral inhibitor of phosphoinositide 3-kinase (PI3K) δ.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: idelalisib

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 100.86
Molecular weight 415.16
XLogP 4.11
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC(c1nc2cccc(c2c(=O)n1c1ccccc1)F)Nc1ncnc2c1[nH]cn2
Isomeric SMILES CC[C@@H](c1nc2cccc(c2c(=O)n1c1ccccc1)F)Nc1ncnc2c1[nH]cn2
InChI InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
InChI Key IFSDAJWBUCMOAH-HNNXBMFYSA-N
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
Approved in combination with rituximab for CLL. Also used to treat relapsed small lymphocytic leukemia (SLL).
non-Hodgkin lymphoma Disease Ontology: DOID:0060060
OMIM: 605027
Approved specifically for relapsed follicular B-cell non-Hodgkin lymphoma.